低中危急性髓细胞白血病缓解后治疗策略及进展

吴德沛, 陈佳. 低中危急性髓细胞白血病缓解后治疗策略及进展[J]. 临床血液学杂志, 2014, 27(3): 175-178. doi: 10.13201/j.issn.1004-2806.2014.03.001
引用本文: 吴德沛, 陈佳. 低中危急性髓细胞白血病缓解后治疗策略及进展[J]. 临床血液学杂志, 2014, 27(3): 175-178. doi: 10.13201/j.issn.1004-2806.2014.03.001
WU Depei, CHEN Jia. Post-remission treatment strategy for acute myeloid leukemia patients in low-or intermediate-risk group[J]. J Clin Hematol, 2014, 27(3): 175-178. doi: 10.13201/j.issn.1004-2806.2014.03.001
Citation: WU Depei, CHEN Jia. Post-remission treatment strategy for acute myeloid leukemia patients in low-or intermediate-risk group[J]. J Clin Hematol, 2014, 27(3): 175-178. doi: 10.13201/j.issn.1004-2806.2014.03.001

低中危急性髓细胞白血病缓解后治疗策略及进展

  • 基金项目:

    江苏省临床医学中心(No:ZX201102)

    国家临床重点专科建设项目

    卫生公益性行业科研专项经费项目(No:201202017)

    国家高技术研究发展计划(863计划)课题(No:2012AA02A505)

详细信息
    作者简介:

    吴德沛,主任医师,教授,博士生导师,国家重点学科苏州大学附属第一医院血液科主任、江苏省血液研究所副所长、苏州大学临床医学研究院副院长。享受国务院特殊津贴,任第九届中华医学会血液学分会副主任委员、中华医学会血液学分会实验诊断学组组长,第二届中国医师协会血液科医师分会副会长,第五、六届江苏省血液学会主任委员,江苏省血液病质量控制中心主任。从事内科血液病临床工作30年,以造血干细胞移植为主要研究方向,擅长白血病等恶性血液病的现代诊治。

    通讯作者: 吴德沛,E-mail:wudepei@medmail.com.cn
  • 中图分类号: R733.71

Post-remission treatment strategy for acute myeloid leukemia patients in low-or intermediate-risk group

More Information
  • 加载中
  • [1]

    THOMAS X,ELHAMRI M,RAFFOUX E,et al.Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission:the ALFA-9802 study[J].Blood,2011,118:1754-1762.

    [2]

    LOWENBERG B,PABST T,VELLENGA E,et al.Cytarabine dose for acute myeloid leukemia[J].N Eng J Med,2011,364:1027-1036.

    [3]

    BURNETT A K,RUSSELL N H,HILLS R K,et al.Optimization of chemotherapy for yonger patients with acute myeloid leukemia:results of the medical research council AML15 trial[J].J Clin Oncol,2013,31:3360-3368.

    [4]

    HENGEVELD M,SUCIU S,KARRASCH M,et al.Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years:final results of the randomized phased III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia cooperative Groups[J].Ann Hematol,2012,91:825-835.

    [5]

    KEATING A,DASILVA G,PÉREZ W S,et al.Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete:a registry study from the Center for International Blood and Marrow Transplantation Research[J].Haematologica,2013,98:185-192.

    [6]

    ETO T,TAKASE K,MIYAMOTO T,et al.Autologous peripheral blood stem cell transplantation with granulocyte colony-stimulating factor combined conditioning regimen as a postremission therapy for acute myelogenous leukemia in first complete remission[J].Int J Hematol,2013,98:186-196.

    [7]

    STAUDINGER M,HUMPE A,GRAMATZKI M.Strategies for purging CD96+ stem cells in vitro and in vivo:New avenues for autologous stem cell transplantation in acute myeloid leukemia[J].Oncoimmunology,2013,2:e24500.

    [8]

    HUANG X J,ZHU H H,CHANG Y J,et al.The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-or high-risk aucte myloid leukemia in first complete remission[J].Blood,2012,119:5584-5590.

    [9]

    BURNETT A K,GOLDSTONE A,HILLS R K,et al.Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remisson[J].J Clin Oncol,2013,31:1293-1301.

    [10]

    CHEN J,WANG R X,CHEN F,et al.Combination of a haploidentical SCT with an unrelated cord blood unit:a single-arm prospective study[J].Bone Marrow Transplant,2014,49:206-211.

    [11]

    SANCHEZ-ORTEGA I,ARNAN M,PATINO B,et al.Early engraftment and full-donor chimerism alter single-cord blood plus third-party donor dual transplantation in patients with high-risk acute leukemia[J].Bone Marrow Transplant,2014,49:145-147.

    [12]

    MIYAWAKI S,OHTAKE S,FUJISAWA S,et al.A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremissoin therapy for acute myloid leukemia in adults:the JALSG AML201 Study[J].Blood,2011,117:2366-2372.

    [13]

    GUO M,HU K X,YU C L,et al.Infusion of HLA-mismatched periperal blood stem cells pmproves the outcome of chemotherapy for aucte myeloid leukemia in elderly patients[J].Blood,2011,117:936-941.

  • 加载中
    Created with Highcharts 5.0.7访问量Chart context menu近一年内文章摘要浏览量、PDF下载量统计信息摘要浏览量PDF下载量2024-072024-082024-092024-102024-112024-122025-012025-022025-032025-032025-04012345Highcharts.com
    Created with Highcharts 5.0.7Chart context menu访问类别分布HTML全文: 100.0 %HTML全文: 100.0 %HTML全文Highcharts.com
    Created with Highcharts 5.0.7Chart context menu访问地区分布其他: 11.1 %其他: 11.1 %上海: 4.2 %上海: 4.2 %北京: 4.2 %北京: 4.2 %张家口: 5.6 %张家口: 5.6 %济南: 1.4 %济南: 1.4 %漯河: 4.2 %漯河: 4.2 %石家庄: 1.4 %石家庄: 1.4 %芒廷维尤: 59.7 %芒廷维尤: 59.7 %芝加哥: 4.2 %芝加哥: 4.2 %西宁: 2.8 %西宁: 2.8 %郑州: 1.4 %郑州: 1.4 %其他上海北京张家口济南漯河石家庄芒廷维尤芝加哥西宁郑州Highcharts.com
计量
  • 文章访问数:  234
  • PDF下载数:  97
  • 施引文献:  0
出版历程
收稿日期:  2013-11-18

目录